# China Liquid Biopsy Market > China Liquid Biopsy Market Research Report: Size, Share, Trend Analysis By Typess (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, Others), By Applications (Cancer Therapeutic Application, Reproductive Health, Others), and By Sample (Blood Sample, Urine Sample, Other) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.53% - **2024:** $ 636.93 Million - **2025:** $ 704 Million - **2035:** $ 1,915 Million - **Key Players:** Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Qiagen (DE), Thermo Fisher Scientific (US) **Report ID:** MRFR/HC/42984-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-liquid-biopsy-market-44664 --- ## Market Summary ## **China Liquid Biopsy Market Overview** As per MRFR analysis, the China Liquid Biopsy Market Size was estimated at 494.03 (USD Million) in 2023.The China Liquid Biopsy Market Industry is expected to grow from 546.0(USD Million) in 2024 to 1,641.0 (USD Million) by 2035. The China Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.522% during the forecast period (2025 - 2035) ## **Key China Liquid Biopsy Market Trends Highlighted** China's liquid biopsy market is experiencing significant trends driven by rapid advancements in technology and increasing investment in healthcare research. The growing burden of cancer, which remains a leading cause of death in China, is pushing for more effective and less invasive diagnostic tools like liquid biopsies. The government's focus on enhancing cancer screening and early diagnosis is evident through various health initiatives and policies aimed at improving patient outcomes. This has led to a rising adoption of liquid biopsy techniques among healthcare professionals and institutions. Opportunities in the China liquid biopsy market are expanding as awareness of genetic testing and personalized medicine grows.With a large population and a rising incidence of cancer, there is a substantial demand for non-invasive diagnostic solutions. Companies are increasingly investing in R to develop advanced technologies for circulating tumor DNA (ctDNA) analysis, which is a key area of exploration within the market. Collaborations between academic institutions and biotech firms are becoming more common, further driving innovation and product development. Recently, there has been a trend toward integrating artificial intelligence and machine learning in liquid biopsy analyses, improving the accuracy and efficiency of testing processes. Regulatory bodies in China are also streamlining approval processes for liquid biopsy tests, which supports quicker market access for new technologies.As healthcare systems evolve, the adoption of liquid biopsies is likely to increase, reflecting a shift towards more personalized and precise patient care. Overall, the trends indicate a growing recognition of the potential of liquid biopsy technologies in transforming cancer diagnostics in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **China Liquid Biopsy Market Drivers** **Rising Incidence of Cancer in China** The increasing number of cancer cases in China is a significant driver for the China Liquid Biopsy Market industry. According to the National Cancer Center of China, about 4.57 million new cancer cases were reported in 2020, marking a 30% increase compared to 2015 figures. This alarming rise in cancer rates underscores the urgent need for advanced diagnostic technologies, including liquid biopsies, which are less invasive compared to traditional methods.The Chinese government is actively promoting early cancer detection programs, which further fuels the demand for innovative solutions, thereby contributing to the growth of the liquid biopsy market. **Technological Advancements in Diagnostic Methods** Technological innovation significantly enhances the capabilities of the China Liquid Biopsy Market industry. Major corporations such as Tencent and BGI Group are investing in research and development to improve liquid biopsy technologies, contributing to more accurate and sensitive detection of cancer biomarkers. According to the Ministry of Science and Technology of China, investment in biotechnology has surged by over 12% annually since 2018, fostering an environment that encourages rapid development of liquid biopsy methodologies.These advancements not only improve diagnosis but also expand the scope of liquid biopsies for cancer monitoring and treatment response evaluation. **Government Support and Regulatory Framework** The development of the China Liquid Biopsy Market is further driven by China's encouraging government policies. Policies designed to encourage the development of precision medicine and early diagnosis have been put in place, motivating firms to seek new ways to puncture the liquid biopsy industry. The State Council of China hopes to greatly advance in cancer control and prevention and is looking forward to greatly increasing the funding allocated to early detection programs.With such policies paving the way for better funding and support for liquid biopsy technologies, the market is poised for robust growth as more companies enter this promising sector. **Growing Public Awareness and Acceptance** Public awareness about the importance of early cancer detection is growing in China, creating a favorable environment for the China Liquid Biopsy Market industry. Education campaigns supported by health organizations and hospitals are playing a crucial role in informing the populace about the benefits of liquid biopsy tests over traditional tissue biopsies. As per reports from the Chinese Center for Disease Control and Prevention, there has been a 20% increase in awareness about liquid biopsy tests among patients seeking cancer screenings in the past three years.This growing acceptance is driving demand for liquid biopsy services, thus fostering market growth. ## **China Liquid Biopsy Market Segment Insights** ### **Liquid Biopsy Market Types Insights** The China Liquid Biopsy Market is experiencing notable growth, driven by the advancement of diagnostic technologies and an increasing emphasis on non-invasive testing methods. Liquid biopsy, which involves analyzing bodily fluids like blood for cancer biomarkers, has emerged as a pivotal component in cancer management and early detection, enabling timely diagnosis and personalized treatment plans. Within this market, several types are recognized, including Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and others, each playing an essential role in understanding tumor dynamics and patient-specific responses. Circulating Tumor Cells represent a critical area as they provide insights into tumor progression by allowing clinicians to monitor metastasis and treatment efficacy. Their ability to be isolated and analyzed provides invaluable data for real-time decision-making in oncology. Circulating Tumor DNA, on the other hand, has gained significant traction due to its potential for offering genetic information about the tumor's mutations and alterations, which is vital for targeted therapies. The non-invasive nature of ctDNA testing adds to its appeal, making it an integral tool in precision medicine and biomarker research. Extracellular Vesicles, which include exosomes, are significant carriers of molecular information, reflecting the tumor microenvironment and facilitating intercellular communication. Their analysis can provide insights into the tumor's molecular makeup and its biological activity, offering promising opportunities for developing new therapeutic strategies. Moreover, the segment categorized as 'Others' encompasses a broad range of emerging techniques and methodologies, which continue to evolve as research in liquid biopsies expands. This diversification within the China Liquid Biopsy Market segmentation illustrates the dynamic nature of cancer diagnostics and the potential for improving patient outcomes through early detection and treatment personalization. Factors such as an aging population, rising cancer incidence, and a growing preference for non-invasive techniques are expected to significantly drive market developments. Furthermore, challenges like regulatory hurdles and the need for robust clinical validation remain prominent but also present opportunities for innovation and growth within the industry. The combination of these elements positions the China Liquid Biopsy Market as a critical frontier in oncology, contributing to advancements in medical science and improved healthcare delivery in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Liquid Biopsy Market Application Insights** The China Liquid Biopsy Market is experiencing notable advancements, particularly within the Application segment, which includes key areas such as Cancer Therapeutic Application, Reproductive Health, and others. Cancer Therapeutic Applications play a critical role in early detection and personalized treatment, with liquid biopsies becoming integral in monitoring tumor progression and response to therapy. This segment is significant as it empowers healthcare providers to tailor treatments based on real-time insights into patients' conditions. Reproductive Health is gaining traction, focusing on prenatal testing and genetic screenings, essential for assessing risks and ensuring healthy pregnancies.This segment highlights the increasing awareness and demand for non-invasive testing methods among expectant parents in China. Other applications within the Liquid Biopsy Market further explore various diagnostic purposes, showcasing the versatility and growing potential of liquid biopsies in diverse healthcare fields. The market is bolstered by technological advancements and an evolving regulatory framework in China, driving the adoption of liquid biopsy solutions and addressing the rising burden of cancer and reproductive health issues. These factors collectively underline the significance of the Application segment within the China Liquid Biopsy Market, positioning it for sustained growth and innovation. ### **Liquid Biopsy Market Sample Insights** The China Liquid Biopsy Market is evolving significantly, with a focus on various sample types, including blood, urine and others. Blood samples are particularly critical due to their ability to provide comprehensive genomic information, making them a popular choice for cancer diagnosis and monitoring. Urine samples, on the other hand, are gaining traction due to their non-invasive nature and ease of collection, which aligns well with patient preferences and regulatory compliance in China. The growing incidence of cancer and the increasing demand for early detection methods are driving the relevance of these sample types in the liquid biopsy landscape.Furthermore, advancements in technology and analytical methods are enhancing the accuracy and reliability of liquid biopsy tests, thereby reinforcing their importance in clinical settings. As a result, the segments within the China Liquid Biopsy Market are poised to witness robust growth, contributing significantly to market dynamics and service offerings in precision medicine. **China Liquid Biopsy Market Key Players and Competitive Insights** The China Liquid Biopsy Market is witnessing a significant transformation propelled by innovations in molecular diagnostics and a growing emphasis on precision medicine. As healthcare systems aim to adopt less invasive and more accurate testing methodologies, liquid biopsy technologies have emerged as a prominent alternative to traditional tissue biopsies. This market is characterized by strategic collaborations, advancements in technology, and the establishment of regulatory frameworks to facilitate rapid growth. Competition in this landscape is driven not only by technological capabilities but also by partnerships between biopharmaceutical companies and research institutions, enhancing the scope and effectiveness of liquid biopsy applications in cancer diagnosis and monitoring.FudanZhangjiang BioPharmaceutical has carved a substantial niche in the China Liquid Biopsy Market, leveraging its strengths in research and development. The company is known for its strong focus on developing innovative platforms for liquid biopsy solutions that cater specifically to cancer detection and personalized medicine. FudanZhangjiang BioPharmaceutical has been active in building partnerships with leading hospitals and research institutions in China, which bolsters its market presence and operational efficacy. By continuously refining its technologies and enhancing its product offerings, the company positions itself favorably against competitors, demonstrating a commitment to revolutionizing cancer diagnostics in the region. Its specialized expertise and infrastructural investments play a crucial role in addressing the increasing demand for non-invasive cancer testing solutions across the Chinese healthcare system.Horizon Discovery has also established a solid footing in the China Liquid Biopsy Market, focusing on providing advanced molecular tools and services essential for precision medicine. The company emphasizes the development of key products related to gene editing and genomic analysis, which are critical in the context of liquid biopsy applications. Horizon Discovery has a strategic presence in the region through collaborations with local biotech firms and healthcare organizations aimed at advancing liquid biopsy technologies. The company’s strengths lie in its innovative research capabilities and its comprehensive service offerings that amplify its market authority. Horizon Discovery has pursued growth through various mergers and acquisitions, enhancing its technological portfolio and expanding its reach within China. This approach not only enriches its product line but also solidifies its position as a key player in the . **Key Companies in the China Liquid Biopsy Market Include** **China Liquid Biopsy Market Industry Developments** In recent developments within the China Liquid Biopsy Market, significant strides have been observed among key players such as FudanZhangjiang BioPharmaceutical and BGI. Notably, in October 2023, BGI announced advancements in its NGS-based liquid biopsy technologies, enhancing early cancer detection capabilities. In terms of market growth, the valuation of significant companies like GeneplusBeijing and Sysmex Corporation has surged, largely due to increased investments in oncology diagnostics and growing adoption of liquid biopsy technologies across healthcare facilities in China. Furthermore, mergers and acquisitions amid this competitive landscape have gained momentum, with GeneCast recently acquiring Nanjing Geneseeq Technology to expand its product offerings, an event reported in July 2023. Major happenings from earlier years include the establishment of a comprehensive regulatory framework by the Chinese National Medical Products Administration in April 2022, which further stimulated market growth by promoting innovations in liquid biopsy testing. As the demand for non-invasive diagnostic methods continues to escalate, companies like Guangzhou Jusda Healthcare Technology and MediSapiens are positioning themselves strategically to capture new market opportunities, making the China liquid biopsy segment vibrant and rapidly evolving. ## **China Liquid Biopsy Market Segmentation Insights** ### **China****Liquid Biopsy Market****Types****Outlook** - ### **China****Liquid Biopsy Market****Application****Outlook** - ### **China****Liquid Biopsy Market****Sample****Outlook** - ## Market Drivers ### Rising Incidence of Cancer The increasing incidence of cancer in China is a primary driver for the liquid biopsy market. With cancer cases projected to rise significantly, the demand for non-invasive diagnostic methods is likely to grow. Liquid biopsies offer a less invasive alternative to traditional tissue biopsies, allowing for earlier detection and monitoring of cancer progression. According to recent statistics, cancer is expected to account for approximately 23% of all deaths in China by 2030. This alarming trend underscores the necessity for innovative diagnostic solutions, positioning the liquid biopsy market as a critical component in the fight against cancer. As healthcare providers seek efficient and effective diagnostic tools, the liquid biopsy market is poised for substantial growth, potentially reaching a valuation of $2 billion by 2027. ### Increased Healthcare Expenditure China's rising healthcare expenditure is a significant driver for the liquid biopsy market. The government has been investing heavily in healthcare infrastructure and services, aiming to improve access to advanced diagnostic tools. In 2025, healthcare spending is projected to reach approximately $1 trillion, reflecting a commitment to enhancing patient care. This increase in funding is likely to facilitate the adoption of innovative technologies, including liquid biopsies, which are seen as essential for early cancer detection and monitoring. The liquid biopsy market stands to benefit from this trend, as healthcare providers seek to integrate cost-effective and efficient diagnostic solutions into their practices, potentially leading to a market growth rate of 20% over the next five years. ### Advancements in Genomic Technologies Technological advancements in genomic sequencing and analysis are propelling the liquid biopsy market forward in China. Innovations such as next-generation sequencing (NGS) and digital PCR are enhancing the sensitivity and specificity of liquid biopsies. These technologies enable the detection of circulating tumor DNA (ctDNA) and other biomarkers with unprecedented accuracy. As a result, healthcare professionals can make more informed decisions regarding treatment options. The liquid biopsy market is experiencing a surge in research and development investments, with funding increasing by approximately 15% annually. This trend suggests a robust future for liquid biopsies, as they become integral to personalized medicine and targeted therapies, ultimately improving patient outcomes. ### Growing Awareness of Early Detection There is a growing awareness among the Chinese population regarding the importance of early cancer detection, which is driving the liquid biopsy market. Public health campaigns and educational initiatives are emphasizing the benefits of early diagnosis, leading to increased demand for non-invasive testing methods. Liquid biopsies are gaining traction as they provide timely insights into cancer progression without the need for invasive procedures. This shift in public perception is likely to result in a higher adoption rate of liquid biopsies, as patients and healthcare providers alike recognize their potential. The liquid biopsy market is expected to capitalize on this trend, with an anticipated market growth of 18% annually as more individuals seek out these innovative diagnostic options. ### Regulatory Support for Innovative Diagnostics Regulatory support for innovative diagnostic methods is fostering growth in the liquid biopsy market. The Chinese government has been actively promoting the development and approval of advanced diagnostic technologies, streamlining the regulatory process for liquid biopsies. This supportive environment encourages research and development, allowing companies to bring their products to market more efficiently. As a result, the liquid biopsy market is likely to see an influx of new products and technologies, enhancing competition and driving innovation. With regulatory bodies prioritizing patient safety and efficacy, the liquid biopsy market is positioned for robust growth, potentially expanding by 25% over the next few years as new solutions become available. ## Future Outlook The [Liquid Biopsy Market](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) in China is projected to grow at a 10.53% CAGR from 2025 to 2035, driven by technological advancements and increasing cancer prevalence. **New opportunities:** - Development of portable liquid biopsy devices for remote diagnostics. Partnerships with healthcare providers for integrated testing solutions. Expansion into personalized medicine through targeted biomarker identification. By 2035, the liquid biopsy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Cancer Diagnosis (Largest) vs. Treatment Monitoring (Fastest-Growing) In the China liquid biopsy market, the application segment is primarily driven by Cancer Diagnosis, which holds the largest market share. This segment benefits from an increasing prevalence of cancer in the region, leading to higher demand for early and accurate diagnosis methodologies. Treatment Monitoring and Recurrence Monitoring are also significant contributors, showcasing their importance in the overall healthcare continuum. Clinical Trials and Research Applications, though smaller, play crucial roles in advancing liquid biopsy technologies and methodologies. Growth trends indicate a significant rise in the Treatment Monitoring segment, which is now among the fastest-growing segments in the China liquid biopsy market. The increased focus on personalized medicine and the need for real-time monitoring of treatment efficacy drive this growth. Furthermore, advancements in technology and the rising number of clinical studies are expected to bolster growth across all segment values, promoting a more integrated approach to cancer management. Cancer Diagnosis (Dominant) vs. Treatment Monitoring (Emerging) Cancer Diagnosis remains the dominant application in the China liquid biopsy market, attributed to the growing incidences of cancer and the need for efficient diagnostic solutions. This segment is characterized by its established methodologies and high acceptance rate among healthcare professionals for detecting various types of cancers. In contrast, Treatment Monitoring is an emerging segment characterized by rapid technological advancements and the increasing demand for non-invasive monitoring options. Its growth is fueled by the shift towards personalized therapies and the integration of liquid biopsies in clinical settings to evaluate treatment response. As both segments evolve, their interplay will significantly shape future market dynamics. ### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing) In the China liquid biopsy market, the sample type distribution is primarily dominated by blood, which holds the largest market share due to its accessibility and the ability to yield a wide range of biomarker information. Following blood, urine is emerging as a significant player, particularly as a non-invasive option that appeals to patients and healthcare providers alike. Emerging sample types, such as saliva, pleural fluid, and cerebrospinal fluid, also contribute to the diversification of diagnostic methods but hold smaller shares in comparison to the two aforementioned types. Growth in the sample type segment is heavily driven by advances in technology and an increasing shift towards minimally invasive procedures. Blood continues to be a trusted source for cancer diagnostics, while the rising adoption of urine-based tests is notable for early detection and monitoring. Factors such as ongoing research, increased focus on patient comfort, and developments in biomarker identification are propelling this segment forward, particularly enhancing the role of urine in clinical practice. Blood (Dominant) vs. Urine (Emerging) Blood, as a dominant sample type, offers extensive applications in liquid biopsy, including cancer detection and monitoring due to the rich medical information it provides from circulation. Its robust infrastructure and established protocols for blood collection enhance its appeal in clinical settings. In contrast, urine is positioned as an emerging sample type, valued for its non-invasive nature, making it more acceptable for patients. The innovation in urine testing technologies, coupled with the focus on patient-centric approaches, is driving its growth. As researchers continue to uncover new biomarkers in urine, its potential to complement traditional blood tests and provide quick diagnostic outcomes places it at the forefront of the evolving landscape in the China liquid biopsy market. ### By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing) In the China liquid biopsy market, Next Generation Sequencing (NGS) has established itself as the largest segment, capturing a significant share due to its capability for comprehensive genomic analysis. Digital PCR follows closely behind, being recognized as the fastest-growing segment. The adoption of these technologies is fueling rapid growth and is seen as a vital component of clinical diagnostics and research applications. Growth trends in the technology segment are driven primarily by innovations in genetic testing and the increasing prevalence of cancer and genetic disorders. The demand for precise and non-invasive testing methods is propelling advancements in NGS and Digital PCR technologies. Moreover, the integration of microfluidics, exosome isolation, and circulating tumor cells are contributing to enhanced diagnostic capabilities, providing valuable insights for personalized treatment plans. Technology: Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging) Next Generation Sequencing (NGS) continues to dominate the technology segment, showcasing its extensive applications in cancer genomics and personalized medicine. Characterized by its ability to analyze vast amounts of genetic information rapidly, NGS is instrumental in the early detection of malignancies and monitoring treatment responses. Meanwhile, Digital PCR has emerged as a significant player, known for its high sensitivity and accuracy. This technology is particularly effective in quantifying rare mutations and detecting minimal residual disease, making it crucial for effective patient management. As both NGS and Digital PCR evolve, they are likely to complement each other, enhancing the overall landscape of liquid biopsy technologies. ### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) The market share distribution in the China liquid biopsy market reveals that hospitals command the largest segment, driven by their extensive patient bases and advanced infrastructure. Diagnostic laboratories are rapidly catching up, becoming increasingly pivotal as they enhance their capabilities and expand their testing services, which reflects growing demand for accurate and early detection of diseases. Growth trends for this segment are significantly influenced by the increasing prevalence of cancer and other chronic diseases, necessitating innovative diagnostic solutions. The push towards personalized medicine also propels investment in liquid biopsy technologies across all segments, particularly diagnostic laboratories, which are positioned to leverage advancements and streamline testing processes, thus contributing to their status as the fastest-growing segment. Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals play a dominant role in the China liquid biopsy market due to their established patient care protocols and the integration of liquid biopsy tests into routine diagnostics. They benefit from advanced technology and comprehensive care delivery systems, essential for effective patient management. On the other hand, diagnostic laboratories are emerging players characterized by their specialized focus on diagnostic testing. Their agility in adapting to new technologies and dedicated research contributes to a swift expansion, enabling them to cater to increasingly diverse patient needs, thereby positioning them as key innovators in the liquid biopsy landscape. ## Competitive Benchmarking The liquid biopsy market in China is characterized by a rapidly evolving competitive landscape, driven by technological advancements and increasing demand for non-invasive diagnostic solutions. Key players are focusing on innovation and strategic partnerships to enhance their market presence. For instance, Guardant Health (US) has positioned itself as a leader in genomic testing, emphasizing its proprietary technology for detecting cancer through blood samples. Similarly, Roche (CH) is leveraging its extensive experience in diagnostics to integrate [liquid biopsy](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) solutions into its broader portfolio, thereby enhancing its competitive edge. These strategies collectively contribute to a dynamic environment where companies are not only competing on product offerings but also on technological capabilities and market reach.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to better serve the Chinese market. The competitive structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies like Thermo Fisher Scientific (US) and Qiagen (DE) is notable, as they continue to expand their operational footprints and product lines in response to local demand. This competitive interplay fosters an environment where innovation and efficiency are paramount, shaping the overall market dynamics. In October Thermo Fisher Scientific (US) announced a strategic partnership with a leading Chinese healthcare provider to enhance the accessibility of its liquid biopsy tests across the region. This collaboration is expected to significantly improve patient access to advanced diagnostic tools, thereby reinforcing Thermo Fisher's market position. The strategic importance of this partnership lies in its potential to streamline distribution channels and enhance the company's ability to respond to local healthcare needs. In September Qiagen (DE) launched a new liquid biopsy assay specifically designed for early cancer detection, targeting the growing demand for precision medicine in China. This product introduction not only showcases Qiagen's commitment to innovation but also highlights its strategic focus on addressing the unique challenges of the Chinese healthcare landscape. The launch is likely to strengthen Qiagen's competitive position by offering tailored solutions that meet local market requirements. In August Guardant Health (US) expanded its operations in China by establishing a new research and development facility aimed at enhancing its liquid biopsy technologies. This move underscores the company's long-term commitment to the Chinese market and its intention to drive innovation through localized research efforts. The establishment of this facility is expected to facilitate the development of more effective diagnostic solutions, thereby enhancing Guardant's competitive differentiation. As of November current trends in the liquid biopsy market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are playing a crucial role in shaping the competitive landscape, as companies seek to combine their strengths to foster innovation and improve patient outcomes. Looking ahead, it appears that competitive differentiation will increasingly pivot from price-based strategies to a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized healthcare solutions. ## Recent News & Developments In recent developments within the China Liquid Biopsy Market, significant strides have been observed among key players such as FudanZhangjiang BioPharmaceutical and BGI. Notably, in October 2023, BGI announced advancements in its NGS-based liquid biopsy technologies, enhancing early cancer detection capabilities. In terms of market growth, the valuation of significant companies like GeneplusBeijing and Sysmex Corporation has surged, largely due to increased investments in oncology diagnostics and growing adoption of liquid biopsy technologies across healthcare facilities in China. Furthermore, mergers and acquisitions amid this competitive landscape have gained momentum, with GeneCast recently acquiring Nanjing Geneseeq Technology to expand its product offerings, an event reported in July 2023. Major happenings from earlier years include the establishment of a comprehensive regulatory framework by the Chinese National Medical Products Administration in April 2022, which further stimulated market growth by promoting innovations in liquid biopsy testing. As the demand for non-invasive diagnostic methods continues to escalate, companies like Guangzhou Jusda Healthcare Technology and MediSapiens are positioning themselves strategically to capture new market opportunities, making the China liquid biopsy segment vibrant and rapidly evolving. ## Report Scope | MARKET SIZE 2024 | 636.93(USD Million) | | --- | --- | | MARKET SIZE 2025 | 704.0(USD Million) | | MARKET SIZE 2035 | 1915.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.53% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Qiagen (DE), Thermo Fisher Scientific (US) | | Segments Covered | Application, Sample Type, Technology, End Use | | Key Market Opportunities | Advancements in non-invasive cancer diagnostics drive growth in the liquid biopsy market. | | Key Market Dynamics | Rising demand for non-invasive cancer diagnostics drives innovation and competition in the liquid biopsy market. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the liquid biopsy market in China as of 2024?** A: The liquid biopsy market in China was valued at $636.93 Million in 2024. **Q: What is the projected market size for liquid biopsy in China by 2035?** A: The market is projected to reach $1915.0 Million by 2035. **Q: What is the expected CAGR for the liquid biopsy market in China from 2025 to 2035?** A: The expected CAGR for the China liquid biopsy market during the forecast period 2025 - 2035 is 10.53%. **Q: Which application segment had the highest valuation in 2024?** A: In 2024, the Cancer Diagnosis application segment had the highest valuation at $191.39 Million. **Q: What are the projected values for the Treatment Monitoring segment by 2035?** A: The Treatment Monitoring segment is projected to reach $380.0 Million by 2035. **Q: Which sample type is expected to dominate the market in terms of valuation by 2035?** A: The Blood sample type is expected to dominate the market, projected to reach $750.0 Million by 2035. **Q: What technology segment is anticipated to show significant growth by 2035?** A: The Next Generation Sequencing technology segment is anticipated to grow significantly, reaching $385.0 Million by 2035. **Q: Which end-use segment is projected to have the highest valuation in 2035?** A: The Pharmaceutical Companies end-use segment is projected to have the highest valuation at $765.0 Million by 2035. **Q: Who are the key players in the China liquid biopsy market?** A: Key players in the market include Guardant Health, Exact Sciences, Freenome, GRAIL, Biocept, Foundation Medicine, Roche, Qiagen, and Thermo Fisher Scientific. **Q: What is the expected trend for the Recurrence Monitoring segment by 2035?** A: The Recurrence Monitoring segment is expected to grow to $190.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-liquid-biopsy-market-44664*